Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG) - Episode 14

Clinical Scenario 2 - BRAFV600E

August 30, 2024

The key opinion leaders analyze a second clinical scenario, focusing on a patient with a BRAF V600E mutation in their pediatric low-grade glioma (pLGG).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of pLGG presentation and categorization

EP. 2: Molecular Characterization of pLGG

EP. 3: Less Common Molecular Alterations in pLGG and Testing Recommendations

EP. 4: Standard of care for frontline treatment of non-V600E-specific pLGG tumors

EP. 5: Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

EP. 6: Current Treatment of Patients with NF1 pLGG

EP. 7: Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

EP. 8: Treatment Considerations for Progressive pLGG

EP. 9: Radiation and Targeted Therapies for Progressive pLGG

EP. 10: The Role of Tovorafenib in Treatment of Progressive pLGG

EP. 11: Clinical Trials to Increase Treatment Options in the Progressive Setting

EP. 12: Clinical scenario 1 - BRAFKIAA-1549 fusion

EP. 13: Alternatives and Considerations for Clinical Scenario 1

Now Viewing

EP. 14: Clinical Scenario 2 - BRAFV600E

EP. 15: Potential Adverse Events With Targeted Therapies

EP. 16: Clinical Insights: Looking Forward for pLGG